10-Q: UnitedHealth Q3 Earnings Hit by Rising Medical Costs

UnitedHealth Group reported a 50% decline in third-quarter operating earnings and a 61% drop in net earnings attributable to common shareholders, primarily due to elevated medical cost trends and Medicare funding reductions.

Summary

• Consolidated revenues grew 12% to $113.16 billion for the third quarter of 2025 and 12% to $334.35 billion for the nine months ended September 30, 2025.
• Third-quarter earnings from operations decreased 50% to $4.315 billion, while net earnings attributable to common shareholders fell 61% to $2.348 billion.
• The Medical Care Ratio (MCR) increased to 89.9% in Q3 2025 from 85.2% in Q3 2024, driven by elevated medical cost trends and Medicare funding reductions.
• UnitedHealthcare revenues increased 16% to $87.07 billion in Q3, serving 795,000 more people, mainly in Medicare Advantage, but operating earnings decreased 57% to $1.805 billion.
• Optum Health's operating earnings plummeted 88% to $255 million in Q3, impacted by Medicare Advantage funding reductions and member profile changes.
• Optum Rx revenues grew 16% to $39.68 billion in Q3 2025 due to higher script volumes, with operating earnings increasing slightly by 0.3% to $1.549 billion.
• Cash flows from operations for the nine months ended September 30, 2025, were $18.59 billion, a decrease from $21.84 billion in the prior year.
• We repurchased 12.1 million shares for $5.545 billion during the nine months ended September 30, 2025.
• The quarterly cash dividend was increased to an annual rate of $8.84 per share from $8.40 per share.

Sentiment

Score: 3

Explanation: While revenues grew, the significant decline in operating earnings and net earnings for the quarter, coupled with rising medical costs and negative outlooks from credit rating agencies, indicates a challenging period. The positive nine-month net earnings are largely due to a non-recurring item (lower loss on sale of subsidiary) from the prior year, masking underlying operational pressures. The increased dividend and share repurchases are positive but overshadowed by operational headwinds.

Positives

• Consolidated revenues increased 12% for both the three and nine months ended September 30, 2025, reaching $113.16 billion and $334.35 billion, respectively.
• UnitedHealthcare served 795,000 more people, primarily driven by growth in Medicare Advantage.
• Optum Rx revenues grew 16% in Q3 2025 to $39.68 billion due to higher script volumes from new and existing clients and growth in pharmacy services.
• Net earnings attributable to UnitedHealth Group common shareholders for the nine months ended September 30, 2025, increased 36% to $12.046 billion, largely due to a significantly lower loss on sale of subsidiaries compared to the prior year.
• The quarterly cash dividend was increased to an annual rate of $8.84 per share from $8.40 per share.
• We repurchased 12.1 million shares of common stock for $5.545 billion during the nine months ended September 30, 2025.

Negatives

• Third-quarter earnings from operations decreased 50% to $4.315 billion, a significant decline from Q3 2024.
• Third-quarter net earnings attributable to common shareholders decreased 61% to $2.348 billion.
• The Medical Care Ratio (MCR) increased by 4.7 percentage points to 89.9% in Q3 2025, indicating higher medical costs relative to premiums.
• UnitedHealthcare's operating earnings decreased 57% in Q3 2025, impacted by Medicare Advantage funding reductions and elevated medical cost trends.
• Optum Health's operating earnings decreased 88% in Q3 2025, also affected by Medicare Advantage funding reductions and elevated medical cost trends.
• Cash flows from operating activities for the nine months ended September 30, 2025, decreased by $3.246 billion to $18.589 billion.
• Three credit rating agencies (Moody's, S&P Global, Fitch) have a 'Negative' outlook on our senior unsecured debt.

Risks

• Our ability to effectively estimate, price for, and manage medical costs.
• New or changes in existing health care laws or regulations, or their enforcement or application.
• Cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations.
• Reductions in revenue or delays to cash flows received under government programs.
• Changes in Medicare, the CMS star ratings program, or the application of risk adjustment data validation (RADV) audits.
• The DOJ's legal actions concerning our participation in the Medicare program, specifically a False Claims Act lawsuit alleging improper risk adjustment submissions.
• Our ability to maintain and achieve improvement in quality scores impacting revenue.
• Failure to maintain effective and efficient information systems or if our technology products do not operate as intended.
• Risks and uncertainties associated with our businesses providing pharmacy care services.
• Competitive pressures, including our ability to maintain or increase our market share.
• Changes in or challenges to our public sector contract awards.
• Failure to achieve targeted operating cost productivity improvements.
• Failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals, and other service providers.
• The impact of potential changes in tax laws and regulations.
• Increases in costs and other liabilities associated with litigation, government investigations, audits, or reviews.
• Failure to complete, manage, or integrate strategic transactions.
• Risks and uncertainties associated with the sale of our remaining operations in South America.
• Risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters, and other extreme events.
• Failure to attract, develop, retain, and manage the succession of key employees and executives.
• Our investment portfolio performance.
• Impairment of our goodwill and intangible assets.
• Failure to protect proprietary rights to our databases, software, and related products.
• Downgrades in our credit ratings.
• Our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.

Future Outlook

We expect overall spending on healthcare to continue to grow due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends, and national interest in health and well-being. Pricing trends for 2025 were well short of incurred medical cost trends, significantly impacting earnings. Medicare Advantage funding is expected to remain pressured, and increased care patterns may impact future pricing and benefit design. Medicaid margin percentages face continued downward pressure due to elevated care activity and insufficient funding rates, with some Medicaid membership losses expected in 2026 due to early adoption of recent legislation.

Management Comments

• Our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our earnings.
• We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.
• We have observed increased care patterns, more notably related to physician and outpatient care, and to a lesser extent inpatient and emergency room utilization, that are above what we expected and contemplated in our pricing and benefits design.
• The Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in both increased premiums and medical costs.
• As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period.

Industry Context

The healthcare industry continues to face significant challenges from rising medical costs, driven by inflation, technological advancements, and increased utilization, particularly in physician and outpatient care. Regulatory changes, such as the Inflation Reduction Act, are reshaping the Medicare Part D landscape by shifting more risk to plans. The Medicare Advantage market is under sustained pressure from funding reductions and substantial revisions to risk adjustment models. The Medicaid sector is also struggling with a mismatch between member acuity and state funding rates, exacerbated by redetermination processes. Our performance reflects these broader industry trends, with our core insurance and Optum Health segments experiencing margin compression due to these cost and funding pressures, while Optum Rx shows growth in script volumes.

Management Changes

Corporate Governance

Legal Proceedings

• We are frequently party to a variety of legal actions and regulatory inquiries, including class actions, medical malpractice, employment, intellectual property, antitrust, privacy, and contract claims.
• We are involved in various governmental investigations, audits, and reviews by agencies such as CMS, state insurance departments, OIG, DOJ, and SEC.
• Certain of our businesses are under review for compliance with coding and other requirements under the Medicare risk-adjustment model, including RADV audits.
• A False Claims Act lawsuit, initially filed by a whistleblower in 2011 and pursued by the DOJ since 2017, alleges improper risk adjustment submissions. A Special Master recommended summary judgment in our favor in March 2025, but the DOJ filed a motion to reject this report in April 2025. The outcome cannot be reasonably estimated.

Stakeholder Impact

• Shareholders are impacted by decreased quarterly earnings, increased dividend, and ongoing share repurchase program. Potential for continued volatility due to medical cost trends and regulatory pressures.
• Customers/Members may experience adjustments in benefits and premiums due to increased medical costs and Medicare funding pressures.
• Care Providers are affected by increased audit, clinical policy, and payment integrity tools, and potential changes in network composition.
• Employees are not directly impacted by specific changes mentioned, but general business performance and strategic shifts could indirectly affect employment.
• Regulators maintain ongoing scrutiny through investigations, audits, and legal proceedings, particularly concerning Medicare risk adjustment and compliance.

Next Steps

• Continue to evaluate and adjust our approach in local markets, considering product positioning, price competitiveness, and regulatory considerations.
• Mitigate medical cost increases by engaging hospitals, physicians, and consumers with information and helping them make clinically sound choices.
• Elevate audit, clinical policy, and payment integrity tools to protect customers and patients from unnecessary costs.
• Annually decide on a county-by-county basis where Medicare Advantage plans will be offered.
• Finalize valuation analyses for intangible assets and contingent liabilities related to recent business combinations.
• Close the planned sale of remaining South American operations in the second half of 2026.
• The Board of Directors may further amend the share repurchase program to increase authorized shares.

Key Dates

Recommendation

While UnitedHealth Group demonstrates strong revenue growth and a commitment to shareholder returns through dividends and share repurchases, the significant decline in third-quarter operating and net earnings, driven by elevated medical cost trends and Medicare funding reductions, presents considerable headwinds. The negative outlooks from major credit rating agencies further underscore these challenges. The underlying operational pressures, particularly in UnitedHealthcare and Optum Health, suggest that the company is navigating a difficult environment. The positive nine-month net earnings are largely attributable to a non-recurring item from the prior year, masking the current quarter's operational struggles. Investors should hold to monitor the company's ability to manage medical costs, adapt to regulatory changes, and improve segment profitability in the coming quarters.

Keywords

Healthcare, Managed Care, Health Insurance, Optum, UnitedHealthcare, Medicare Advantage, Medicaid, Pharmacy Benefits, Medical Costs, SEC Filing, Earnings Report, 10-Q, Financial Results, Risk Adjustment, Inflation Reduction Act, Cyberattack Impact